News & Updates

Researchers from the University of Hong Kong (HKU) have developed a dry powder formulation of tamibaroterone, which displays broad-spectrum antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and pandemic 2009 influenza A virus (H1N1), when delivered intranasally or through inhalation in mouse and hamster models.

An infusion of convalescent plasma, obtained via blood donation from individuals who have recovered from COVID-19, did not prevent disease progression in high-risk outpatients who presented within 7 days of COVID-19 symptom onset, results of the phase III US-based SIREN-C3PO* study showed.

A wearable chest patch device can continuously monitor vital signs in patients with the coronavirus disease 2019 (COVID-19), facilitating the early detection of cardiovascular deterioration, according to a recent study.

Late intubation compounds the risk of death among coronavirus disease 2019 (COVID-19) patients on mechanical intubation due to respiratory insufficiency, a recent study has found.

The antiviral monoclonal antibodies casirivimab-imdevimab appear to reduce the risk of hospitalization in patients with nonsevere COVID-19, as do bamlanivimab, bamlanivimab-etesevimab, and sotrovimab, according to the results of a systematic review and meta-analysis.

A manikin study has shown that use of the standard face shield is not enough to protect against droplet dispersion during oropharyngeal COVID-19 swabs, but the SG Shield results in significant reduction of droplet contamination to the swab provider’s face and chest.

Cardiac manifestations, such as acute myocardial infarction (AMI) and myocarditis, after vaccination for the coronavirus disease 2019 (COVID-19) are more common in men, according to a recent Singapore study. AMI is more likely to arise after the first shot, while myocarditis becomes more common after the second dose.